For more information, visit follow us on and LinkedIn. We publish analysis and forecasts to help you choose the right strategies for trading Blueprint Medicines Corporation stock today, tomorrow and in the future. Albers sold 15,000 shares of the stock in a transaction on Friday, November 24th. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. (NASDAQ:BPMC Get Free Report) Director Jeffrey W. On average, equities analysts forecast that Blueprint Medicines Co. The stock was sold at an average price of 50.16, for a total transaction of 501,600.00. Analysts average stock forecasts to be materialized ratio is 60.89 with an average time for these price targets to be met of 140.78 days. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Albers sold 10,000 shares of Blueprint Medicines stock in a transaction that occurred on Friday, August 25th. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Blueprint Medicines Corp News & Analysis Morgan Stanley maintains Blueprint Medicines Corp at equalweight with a price target of 63.00 Oppenheimer Upgrades. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at. and EU non-advanced SM markets, versus $486 million for advanced disease.To access the live conference call, please dial 84 (domestic) or 92 (international), and refer to conference ID 286085. The non-advanced SM population is much larger, and with the latest Pioneer trial readout, Blueprint is targeting about 7,500 non-advanced patients with moderate to severe disease who are currently seeking treatment.īefore Wednesday’s readout, SVB analysts predicted Blueprint’s KIT inhibitor franchise could reach $1.34 billion in the U.S. The Blueprint med also showed a favorable safety profile. Serious side effects occurred in 5% of Ayvakit patients versus 11.3% in the control arm.Īyvakit is currently approved in advanced SM, which only accounts for 5% to 10% of total SM patients. On October 27, 2023, Stellar Bancorp (NYSE:STEL) unveiled its Q3 2023 financial results, showcasing remarkable performance and surpassing market expectations. Cost of Sales: Cost of sales was 7.5 million for the fourth quarter of 2021 and 17.9 million for the year ended December 31, 2021, as compared to 0.1 million for the fourth quarter of 2020 and 0.4. The high estimate was 114.00, while the low estimate was 40.00. Blueprint Medicines recorded 34.1 million and 793.7 million in revenues in the fourth quarter and year ended December 31, 2020, respectively. Currently, there are 60.13 million shares of Blueprint Medicines Corp stock. During the last market session, Blueprint Medicines Corp’s stock traded between 60.67 and 64.03. Blueprint Medicines Corp is up 4.56 from its previous closing price of 63.12. On October 27, 2023, Blueprint Medicines Corp (BPMC) stock had a median target price of 83.50, according to 18 analysts offering 12-month price forecasts. As of July 31, 2023, 4:00 PM CST, Blueprint Medicines Corp’s stock price was 66.00. 2020 and the exercise price of those stock. Blueprint didn’t disclose detailed data for secondary endpoints, saying it will present them at an upcoming medical meeting. Blueprint Medicines Corp (BPMC) Stock Forecast: Positive Outlook and Strong Potential for Growth in 2023. The table below shows the stock options exercised by our non-executive directors during the year ended December 31. That was originally the trial’s primary endpoint until the FDA asked to replace it. Blueprint rounds up $1.25B to grow cancer portfolio through internal R&D and dealmakingĪyvakit also triggered a response in more patients than placebo did as determined by an at-least-30% reduction in the total symptom score.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |